236 related articles for article (PubMed ID: 27644192)
1. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
Mizuno M; Yamano S; Chimura S; Hirakawa A; Takusagawa Y; Sawada T; Maetani S; Takahashi A; Mizuno T; Harada K; Shinoda A; Uchida S; Takeuchi J; Mizukoshi T; Endo M; Uechi M
J Vet Med Sci; 2017 Jan; 79(1):29-34. PubMed ID: 27644192
[TBL] [Abstract][Full Text] [Related]
2. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
[TBL] [Abstract][Full Text] [Related]
4. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
7. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
[TBL] [Abstract][Full Text] [Related]
9. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
de Madron E; King JN; Strehlau G; White RV
Can Vet J; 2011 Nov; 52(11):1219-25. PubMed ID: 22547843
[TBL] [Abstract][Full Text] [Related]
10. Clinical findings and survival time in dogs with advanced heart failure.
Beaumier A; Rush JE; Yang VK; Freeman LM
J Vet Intern Med; 2018 May; 32(3):944-950. PubMed ID: 29635788
[TBL] [Abstract][Full Text] [Related]
11. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
Hezzell MJ; Block CL; Laughlin DS; Oyama MA
J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
[TBL] [Abstract][Full Text] [Related]
12. Pimobendan in heart failure therapy--a silver bullet?
Gordon SG; Miller MW; Saunders AB
J Am Anim Hosp Assoc; 2006; 42(2):90-3. PubMed ID: 16527909
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
[TBL] [Abstract][Full Text] [Related]
14. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
O'Grady MR; Minors SL; O'Sullivan ML; Horne R
J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
[TBL] [Abstract][Full Text] [Related]
15. Pimobendan and its use in treating canine congestive heart failure.
Bowles D; Fry D
Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
[TBL] [Abstract][Full Text] [Related]
16. Use of pimobendan in 170 cats (2006-2010).
Macgregor JM; Rush JE; Laste NJ; Malakoff RL; Cunningham SM; Aronow N; Hall DJ; Williams J; Price LL
J Vet Cardiol; 2011 Dec; 13(4):251-60. PubMed ID: 22030289
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral administration of pimobendan in cats with heart failure.
Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
[TBL] [Abstract][Full Text] [Related]
20. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
